RecruitingNCT06804785
Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)
Sponsor
Northwestern University
Enrollment
800 participants
Start Date
Aug 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to develop a new way to diagnose prostate cancer through the use of artificial intelligence. The goal is for this new method to reduce delays in diagnoses and to avoid invasive procedures such as biopsies.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 89 Years
Inclusion Criteria5
- Elevated PSA (4.0-10.0 ng/ml) or abnormal digital rectal exam with PSA of 2.00-10.00 ng/ml as indicated in the patient's lab report.
- Patients must be biopsy naïve, confirmed with patient or medical record.
- Patients must be male, ≥18 and ≤ 89 years of age.
- Patient must have a life expectancy ≥10 years, determined by PI.
- Patients must exhibit an ECOG performance status of 0-2, as noted in their medical record.
Exclusion Criteria7
- Patients who are on a 5-α-reductase inhibitor within 12 months of enrollment, as confirmed by medical record.
- Patients who have had a prostate infection within 1 month of enrollment, as confirmed by medical record.
- Patients who are receiving or who received prostate cancer treatment (e.g., androgen deprivation therapy, surgery, radiation therapy or adjuvant/neoadjuvant therapy with investigational drugs) per their medical record.
- Patients who've had an invasive urological procedure within 1 month of enrollment, as confirmed by their medical record and patient reporting.
- Patients with no access to the rectum for a transrectal ultrasound, as determined by the Urologist.
- Patients with a contraindication to magnetic resonance imaging (MRI).
- Vulnerable populations: Prisoners or adult men \>89 years old.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06804785
Related Trials
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT020646731 location